Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

Hiroshi Ishikuro

Yoshio Ueda

Osamu Aoki

Norio Ohnishi

Atsuo Ohike

Kazuto Okimoto

Takehisa Hata

Rinta Ibuki

Kazutake Kado

Toshinobu Uemura

Kiyohide Shinooka

Toshiaki Okhuma

This invention relates to a vitreous form of 8-[3-[N-[(E)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (FR173657). This vitreous form has good solid stability and, therefor, is useful for producing and supplying FR173657 products whose quality is stable enough to be suitable for medicines.

Vitreous form of known bradykinin antagonist

The invention relates to a vitreous form of the compound, FR 173657, having the structure of formula (I). This vitreous form has good solid stability and is therefore useful for producing and supplying FR 173657 products whose quality is stable enough to be suitable for medicine.

The present invention relates to a pharmaceutical composition for percutaneous drug absorption which comprises 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and ethanol and/or an unsaturated higher fatty acid and to a composition of matter which comprises ethanol and/or an unsaturated higher fatty acid and is capable of promoting percutaneous absorption of said dihydropyridine compound.

Pharmaceutical composition for percutaneous drug absorption and

The invention relates to a pharmaceutical oral capsule preparation filled with a substantially anhydrous mixture which is in solid or semi-solid form comprising:

Novel drug carrier and pharmaceutical preparation comprising the same

Growing community of inventors

Itami, Japan

Hiroshi Ishikuro